Cybersecurity has moved from back-office necessity to the market’s AI safety trade. The sector is catching a bid as companies face a harder problem than buying more chips. This week’s trigger came from AI leaders warning that model development may be moving faster than safety controls.
Security stocks lead software
CrowdStrike and Palo Alto Networks led a software rally this week. They rose on Monday morning as the iShares Expanded Tech-Software Sector ETF gained 2% amid the rotation.
The same AI fears weighing on infrastructure stocks are creating an opening for cybersecurity. Investors have spent much of 2026 asking whether AI threatens software vendors, but security is starting to look like one area where it could create more demand instead.
As AI agents gain the ability to write code, navigate systems, and act online, companies have more activity to secure. That puts more weight on endpoint protection, identity controls, and network monitoring as businesses give AI greater access to their systems.
CrowdStrike, Palo Alto, Okta, Zscaler, SentinelOne, Fortinet, and Cloudflare are positioned across those layers. Their products solve different problems, but the investment case increasingly comes back to the same point. More capable AI gives companies more to protect.
AI leaders changed the trade
The pressure started after Anthropic CEO Dario Amodei argued that frontier AI labs should slow development so safety work can catch up. OpenAI CEO Sam Altman also warned that AI progress could go badly if humans lose control or power concentrates too tightly.
"We must slow the pace at which we improve the capabilities of A.I. models."
Dario Amodei, Anthropic.
Hardware stocks moved the other way. Nvidia, Marvell, Advanced Micro Devices, and Intel fell early Monday as investors weighed whether slower model development could reduce chip spending across the AI complex.
Cancer vaccines get another shot
Moderna has given its cancer platform fresh momentum. Its personalized vaccine intismeran delivered positive Phase 3 results in melanoma versus KEYTRUDA, giving the program its strongest validation yet.
President Stephen Hoge said the results support Moderna’s strategy of priming T cells to recognize mutations unique to each tumor. “This is T-cell priming, not T-cell exhaustion,” Hoge said.
The next test is whether intismeran can repeat that success beyond melanoma. Moderna and Merck have nine trials underway, including Phase 3 lung cancer studies and fully enrolled Phase 2 programs in kidney and bladder cancers.
Moderna has already treated about 3K patients and built an automated facility in Marlborough to support production as the program expands.
Midcaps move toward decisions
Compass Pathways is approaching a major regulatory milestone as its rolling new drug application moves toward Q4 completion.
Oppenheimer reiterated its Outperform rating after positive 52-week trial data and kept its $20 price target. Shares have gained about 22% over the past three months as the filing moves closer.
Scholar Rock has an FDA decision due Sept. 30. Pharvaris and Travere Therapeutics have also gained momentum, though both look more stretched on weekly relative strength.
Funds spread the risk
One failed trial or delayed approval can quickly reset a biotech stock. Diversified funds spread that company-specific risk while keeping investors exposed to new drug development.
The VanEck Biotech ETF is up about 22% YTD and holds larger US-listed biotech names including Amgen. The iShares Biotechnology ETF also holds Gilead Sciences, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals.
The Global X Genomics & Biotechnology ETF focuses on gene editing, sequencing, genetic medicines, and diagnostics. The ALPS Medical Breakthroughs ETF targets companies with at least one drug in Phase 2 or Phase 3 trials.
Single stocks can deliver bigger gains when the science lands, while funds keep one failed readout from defining the entire bet.